DHT (Dihydrotestosterone): The Hormone Behind BPH & Hair Loss

Dihydrotestosterone (DHT) is the most potent androgen in the male body — approximately five times more powerful than testosterone at the androgen receptor. It is produced when the enzyme 5-alpha reductase converts testosterone inside target tissues, primarily the prostate, scalp, and skin. DHT drives prostate cell proliferation, male-pattern hair loss, and deep libido. It is also almost never measured on standard hormone panels — which means most men managing BPH, hair loss, or hormonal symptoms are flying blind on the most biologically active androgen they produce [1].

What DHT Does in the Male Body

DHT is not a derivative byproduct. It is the primary androgen responsible for several of the most defining characteristics of male physiology — both beneficial and problematic. Understanding what DHT drives explains why the same hormone underlies both peak sexual function and the most common male health complaints after 40.

• •Prostate growth: DHT is the principal hormonal driver of prostate cell proliferation. The prostate contains extremely high concentrations of Type 2 5-alpha reductase, efficiently converting testosterone to DHT locally. Men with genetic 5-alpha reductase deficiency (Type 2) — studied in isolated populations in the Dominican Republic — have essentially no BPH and minimal prostate growth despite normal testosterone [1]. This single natural experiment established DHT, not testosterone, as the BPH driver.
• •Male-pattern androgenetic alopecia: DHT binds androgen receptors in genetically susceptible scalp follicles and shortens the anagen (growth) phase of the hair cycle. Scalp DHT concentration, not serum DHT, is the proximal driver — but serum DHT correlates with scalp exposure.
• •Libido and sexual drive: DHT acts at CNS androgen receptors to drive sexual motivation and erection quality. Men treated with finasteride who experience post-finasteride syndrome report libido loss as the dominant complaint — reflecting DHT's direct role in male sexual CNS function.
• •Clitoris/penis development in utero: DHT is required for complete external genital masculinization during fetal development — 5-alpha reductase deficiency produces ambiguous genitalia despite normal testosterone.
• •Body hair and sebum production: DHT drives terminal body hair growth and sebaceous gland activity. High DHT → increased body hair, oilier skin.
• •Bone density (indirect): DHT contributes to trabecular bone maintenance through androgen receptor activation in osteoblasts, complementary to testosterone's role.

The 5-Alpha Reductase Enzyme — Type 1 vs Type 2

Two isoforms of 5-alpha reductase produce DHT in different tissue compartments, which is why drugs targeting only one isoform produce different clinical effects.

• •Type 1 (SRD5A1): Expressed primarily in liver, skin, and scalp. Responsible for systemic DHT production and scalp DHT generation. Inhibited by dutasteride but not finasteride.
• •Type 2 (SRD5A2): Expressed primarily in prostate, seminal vesicles, and epididymis. The dominant isoform driving prostatic DHT accumulation and BPH. Inhibited by both finasteride and dutasteride.
• •Finasteride (Proscar/Propecia): Inhibits Type 2 only — reduces serum DHT by approximately 65–70% and prostate tissue DHT by approximately 85–90%. Effective for BPH and hair loss but does not fully suppress systemic DHT.
• •Dutasteride (Avodart): Inhibits both Type 1 and Type 2 — reduces serum DHT by approximately 90–95%. More complete DHT suppression, larger prostate volume reduction in clinical trials [4].
• •Saw palmetto: In vitro evidence for 5-alpha reductase inhibition [5]; clinical DHT reduction less consistent than pharmaceutical inhibitors but may offer partial effect without sexual side effect profile of finasteride.

DHT Normal Range for Men and How It Changes With Age

Serum DHT reference ranges vary by laboratory assay method — LC-MS/MS (mass spectrometry) is significantly more accurate than immunoassay for DHT measurement in men. Request LC-MS/MS DHT if ordering; standard immunoassay DHT can be inaccurate by 30–40% in the male range.

• •Ages 18–30: DHT typically 30–85 ng/dL (1.03–2.92 nmol/L)
• •Ages 30–50: DHT typically 25–75 ng/dL — gradual decline parallels falling testosterone
• •Ages 50–70: DHT typically 20–65 ng/dL — despite lower absolute levels, prostate tissue DHT can remain elevated due to upregulated local 5-alpha reductase activity
• •DHT:Testosterone ratio: Typically 0.05–0.12 (DHT is roughly 5–12% of total T). Rising ratio suggests increased 5-alpha reductase activity — relevant for BPH and hair loss risk assessment.
• •Key nuance: serum DHT does not fully reflect tissue DHT. Prostate tissue DHT can be 5–10× higher than serum DHT due to local enzymatic amplification. This is why serum DHT alone is insufficient to assess prostate androgen exposure.

High DHT: Symptoms, Signs, and Clinical Consequences

• •Accelerated BPH progression: Elevated serum DHT correlates with faster prostate volume growth and worsening IPSS scores in longitudinal studies [2]. Men with DHT in the upper quartile of normal have significantly higher rates of urinary retention over 5-year follow-up.
• •Accelerated male-pattern hair loss: High DHT + androgenetically susceptible follicles = faster miniaturization. Serum DHT elevation is not required — scalp follicle sensitivity varies genetically — but elevated serum DHT increases exposure.
• •Increased acne in adult men: DHT is the primary stimulator of sebaceous gland activity; elevated DHT in adult men produces persistent oiliness and cystic acne particularly on jaw, back, and chest.
• •Aggression and mood dysregulation: DHT acts at neurosteroid receptors differently from testosterone; evidence links very high DHT to irritability and emotional lability in some men, though the CNS literature is less definitive than for prostate effects.
• •Polycythemia risk in TRT patients: Exogenous testosterone converts to DHT; men on TRT with high DHT and elevated hematocrit may have compounded cardiovascular risk through viscosity effects.

Low DHT: When DHT Suppression Goes Too Far

Pharmacological DHT suppression (finasteride, dutasteride) is effective for BPH and hair loss — but comes with side effects in a clinically significant minority of men. Understanding what low DHT produces clarifies why DHT is not simply a 'bad' hormone to eliminate.

• •Post-finasteride syndrome (PFS): A subset of men (estimated 1.4–3.5% in clinical trials, potentially higher in real-world use) develop persistent low libido, erectile dysfunction, and mood changes after stopping finasteride — symptoms that do not resolve with drug cessation. Exact mechanism debated; likely involves neurosteroid DHT depletion at CNS GABA-A and NMDA receptor sites.
• •Reduced libido and erectile quality: DHT is required for CNS sexual motivation; pharmacological suppression reduces libido in approximately 3–6% of men in trial data, significantly more in observational studies.
• •Decreased semen volume: DHT maintains seminal vesicle and epididymal function; DHT suppression reduces ejaculate volume and can impair fertility.
• •Mood effects: DHT has direct neurosteroid activity — its metabolite 3α-androstanediol modulates GABA-A receptors. Suppression can produce anxiety, low mood, and blunted stress resilience in susceptible men.
• •Muscle and strength loss: DHT contributes to androgen receptor activation in skeletal muscle — pharmacological suppression can reduce training response and lean mass maintenance.

How to Measure DHT — Testing Protocol

• •Request: Dihydrotestosterone (DHT) by LC-MS/MS — specify mass spectrometry method; reject immunoassay for clinical decisions
• •Order alongside: Total testosterone, SHBG, calculated free T, estradiol (sensitive LC-MS/MS), LH, FSH
• •Timing: Morning draw (7–10am) — DHT follows testosterone's diurnal rhythm though with a somewhat attenuated amplitude
• •Fasting: Not required for DHT specifically, but fasting optimizes the co-ordered testosterone and insulin panels
• •DHT:T ratio calculation: Divide DHT (ng/dL) by total T (ng/dL). Ratio above 0.12 suggests elevated 5-alpha reductase activity; ratio below 0.04 may indicate reduced enzyme activity (relevant in finasteride users)
• •Retest cadence: Every 6 months if monitoring BPH progression or hair loss treatment; annually for baseline hormonal surveillance in men over 40

How to Lower DHT Naturally — Evidence-Based Strategies

Supplements With 5-Alpha Reductase Inhibition Evidence

• •Saw palmetto (320 mg/day standardized extract): In vitro evidence for 5-alpha reductase inhibition [5]; multiple clinical trials show improvement in IPSS scores and urinary flow comparable to tamsulosin, though DHT reduction is less consistent than finasteride. Favorable safety profile — no sexual side effects in trial data.
• •Beta-sitosterol (60–130 mg/day): Phytosterol that inhibits 5-alpha reductase activity and reduces DHT-driven prostate cell proliferation in vitro. Clinical BPH trials show urinary symptom improvement; direct DHT measurement data limited.
• •Pumpkin seed oil (1,000 mg/day): Contains delta-7-sterols that competitively inhibit 5-alpha reductase. A 2014 randomized controlled trial found significant IPSS improvement vs. placebo over 12 months.
• •Zinc (25–45 mg/day short-term): Zinc directly inhibits 5-alpha reductase activity in prostate tissue — established mechanism. Deficiency associated with elevated prostate DHT. Do not exceed 40 mg/day long-term without copper co-supplementation.
• •Green tea catechins (EGCG, 400–800 mg/day): Moderate 5-alpha reductase inhibitory activity in prostate cell lines; epidemiological data from Japan shows inverse correlation between green tea consumption and prostate volume.
• •Lycopene (15–30 mg/day): Antioxidant that reduces oxidative stress in prostate tissue, which upregulates 5-alpha reductase; indirect DHT modulation.

Dietary and Lifestyle Approaches

• •Reduce refined carbohydrates and sugar: Insulin stimulates 5-alpha reductase activity — hyperinsulinemia drives higher tissue DHT conversion independent of serum testosterone level
• •Increase phytoestrogen intake (flaxseed, soy in moderation): Lignans from flaxseed inhibit both 5-alpha reductase and aromatase; modest DHT-lowering effect with additional cardiovascular benefit
• •Optimize body fat: Visceral adiposity drives insulin resistance which upregulates 5-alpha reductase; men with BMI above 30 have meaningfully higher DHT:T ratios than lean controls
• •Reduce alcohol: Alcohol impairs liver clearance of DHT metabolites and raises estradiol, indirectly affecting the DHT-SHBG-estradiol triangle
• •Spearmint tea (2 cups/day): Anti-androgenic properties documented in PCOS research; weak 5-alpha reductase inhibition; evidence base is modest but side effect profile is zero

Tracking DHT Over Time

DHT trends matter more than single snapshots, particularly for men managing BPH progression or monitoring response to 5-alpha reductase inhibitor therapy. The mancore dashboard lets you plot DHT alongside total testosterone, SHBG, and IPSS scores — so you can see whether rising urinary symptoms track with rising DHT:T ratio, or whether a prostate supplement protocol is measurably shifting your androgenic exposure over quarterly testing cycles.

• •Baseline DHT + DHT:T ratio before starting any 5-alpha reductase inhibitor (natural or pharmaceutical)
• •Retest at 90 days on protocol — finasteride produces DHT reduction within 2 weeks; natural inhibitors require longer observation
• •Monitor IPSS score alongside DHT — the goal is symptom reduction, not minimum DHT number
• •Watch for rising DHT:T ratio without rising total T — indicates upregulated 5-alpha reductase activity, often correlating with worsening insulin resistance
• •Men on finasteride or dutasteride: monitor DHT to confirm suppression is achieving target range (below 20 ng/dL on finasteride; below 10 ng/dL on dutasteride)